Fecal microbiota transplantation (FMT) for Clostridium difficile infection: Focus on immunocompromised patients

Stefano Di Bella, Theodore Gouliouris, Nicola Petrosillo

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Clostridium difficile infection (CDI) is an emerging problem worldwide associated with significant morbidity, mortality, recurrence rates and healthcare costs. Immunosuppressed patients, including HIV-seropositive individuals, solid organ transplant recipients, patients with malignancies, hematopoietic stem cell transplant recipients, and patients with inflammatory bowel disease are increasingly recognized as being at higher risk of developing CDI where it may be associated with significant complications, recurrence, and mortality. Fecal microbiota transplantation (FMT) has proven to be an effective and safe procedure for the treatment of recurrent or refractory CDI in immunocompetent patients by restoring the gut microbiota and resistance to further recurrences. During the last two years the first data on FMT in immunocompromised patients began to appear in the medical literature. Herein we summarize the use of FMT for the treatment of CDI with a focus on immunocompromised patients.

Original languageEnglish
Pages (from-to)230-237
Number of pages8
JournalJournal of Infection and Chemotherapy
Volume21
Issue number4
DOIs
Publication statusPublished - Apr 1 2015

Fingerprint

Clostridium Infections
Clostridium difficile
Immunocompromised Host
Recurrence
Transplants
Mortality
Hematopoietic Stem Cells
Inflammatory Bowel Diseases
Health Care Costs
HIV
Morbidity
Fecal Microbiota Transplantation
Therapeutics
Neoplasms
Transplant Recipients

Keywords

  • Clostridium difficile
  • Fecal microbiota transplantation
  • FMT
  • Immunocompromised
  • Microbiota

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Fecal microbiota transplantation (FMT) for Clostridium difficile infection : Focus on immunocompromised patients. / Di Bella, Stefano; Gouliouris, Theodore; Petrosillo, Nicola.

In: Journal of Infection and Chemotherapy, Vol. 21, No. 4, 01.04.2015, p. 230-237.

Research output: Contribution to journalArticle

@article{2f65e56641aa49c590dfd744e198760f,
title = "Fecal microbiota transplantation (FMT) for Clostridium difficile infection: Focus on immunocompromised patients",
abstract = "Clostridium difficile infection (CDI) is an emerging problem worldwide associated with significant morbidity, mortality, recurrence rates and healthcare costs. Immunosuppressed patients, including HIV-seropositive individuals, solid organ transplant recipients, patients with malignancies, hematopoietic stem cell transplant recipients, and patients with inflammatory bowel disease are increasingly recognized as being at higher risk of developing CDI where it may be associated with significant complications, recurrence, and mortality. Fecal microbiota transplantation (FMT) has proven to be an effective and safe procedure for the treatment of recurrent or refractory CDI in immunocompetent patients by restoring the gut microbiota and resistance to further recurrences. During the last two years the first data on FMT in immunocompromised patients began to appear in the medical literature. Herein we summarize the use of FMT for the treatment of CDI with a focus on immunocompromised patients.",
keywords = "Clostridium difficile, Fecal microbiota transplantation, FMT, Immunocompromised, Microbiota",
author = "{Di Bella}, Stefano and Theodore Gouliouris and Nicola Petrosillo",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.jiac.2015.01.011",
language = "English",
volume = "21",
pages = "230--237",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Fecal microbiota transplantation (FMT) for Clostridium difficile infection

T2 - Focus on immunocompromised patients

AU - Di Bella, Stefano

AU - Gouliouris, Theodore

AU - Petrosillo, Nicola

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Clostridium difficile infection (CDI) is an emerging problem worldwide associated with significant morbidity, mortality, recurrence rates and healthcare costs. Immunosuppressed patients, including HIV-seropositive individuals, solid organ transplant recipients, patients with malignancies, hematopoietic stem cell transplant recipients, and patients with inflammatory bowel disease are increasingly recognized as being at higher risk of developing CDI where it may be associated with significant complications, recurrence, and mortality. Fecal microbiota transplantation (FMT) has proven to be an effective and safe procedure for the treatment of recurrent or refractory CDI in immunocompetent patients by restoring the gut microbiota and resistance to further recurrences. During the last two years the first data on FMT in immunocompromised patients began to appear in the medical literature. Herein we summarize the use of FMT for the treatment of CDI with a focus on immunocompromised patients.

AB - Clostridium difficile infection (CDI) is an emerging problem worldwide associated with significant morbidity, mortality, recurrence rates and healthcare costs. Immunosuppressed patients, including HIV-seropositive individuals, solid organ transplant recipients, patients with malignancies, hematopoietic stem cell transplant recipients, and patients with inflammatory bowel disease are increasingly recognized as being at higher risk of developing CDI where it may be associated with significant complications, recurrence, and mortality. Fecal microbiota transplantation (FMT) has proven to be an effective and safe procedure for the treatment of recurrent or refractory CDI in immunocompetent patients by restoring the gut microbiota and resistance to further recurrences. During the last two years the first data on FMT in immunocompromised patients began to appear in the medical literature. Herein we summarize the use of FMT for the treatment of CDI with a focus on immunocompromised patients.

KW - Clostridium difficile

KW - Fecal microbiota transplantation

KW - FMT

KW - Immunocompromised

KW - Microbiota

UR - http://www.scopus.com/inward/record.url?scp=84930375791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930375791&partnerID=8YFLogxK

U2 - 10.1016/j.jiac.2015.01.011

DO - 10.1016/j.jiac.2015.01.011

M3 - Article

C2 - 25703532

AN - SCOPUS:84930375791

VL - 21

SP - 230

EP - 237

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 4

ER -